quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:22:24·13d
ANALYSTRating
Ionis Pharmaceuticals Inc. logo

Raymond James resumed coverage on Ionis Pharma with a new price target

IONS· Ionis Pharmaceuticals Inc.
Health Care
Original source

Companies

  • IONS
    Ionis Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 21UpdateCanaccord Genuity$110.00
  • Apr 10UpdateRaymond James$104.00
  • Jan 28UpdateBarclays$95.00
  • Oct 8UpdateAnalyst$80.00
  • Sep 26UpdateGoldman$65.00
  • Sep 3UpdateBMO Capital Markets$70.00

Related

  • SEC9h
    SEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.
  • SEC9h
    SEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.
  • ANALYST2d
    Canaccord Genuity initiated coverage on Ionis Pharma with a new price target
  • SEC2d
    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR2d
    Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
  • INSIDER6d
    SEC Form 4 filed by Jenne Kyle
  • INSIDER6d
    SEC Form 4 filed by Parshall B Lynne
  • INSIDER6d
    SEC Form 4 filed by Birchler Brian
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022